secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001193125-23-146313
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics annual meeting elects three Class II directors, ratifies KPMG
-------------------------------------------------------------------------------

- Elected Maha Katabi, Ph.D., Michael M. Morrissey, Ph.D., and Patrick G. Enright as Class II directors to serve until 2026.
- Katabi received 27,427,581 votes for, 1,803,342 withheld; Morrissey 25,666,331 for, 3,564,592 withheld; Enright 29,205,775 for, 25,148 withheld.
- Stockholders ratified KPMG LLP as independent auditor for FY2023 with 35,575,486 votes for, 3,251 against, 12,777 abstentions.
- 44,261,109 shares of Class A common stock were outstanding and entitled to vote as of March 17, 2023 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/0001193125-23-146313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/d443819d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer